Athira Pharma falls as Alzheimer's drug candidate fails to meet study goal
22/06/2022 13:34
** Shares of drug developer Athira Pharmaceuticals ATHA.O
fall 68.5% to $2.66 premarket, the worst performer across
exchanges
** Co says a mid-stage study testing its lead experimental
drug, ATH-1017, in mild-to-moderate Alzheimer's disease patients
did not meet the main goal urn:newsml:reuters.com:*:nGNX68F5qR
** ATH-1017 did not show statistically significant change in
one of the disease biomarkers for the full study population -
ATHA
** Stock was down about ~35% YTD as of last close
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))